<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37221349</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-198X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pediatric nephrology (Berlin, Germany)</Title><ISOAbbreviation>Pediatr Nephrol</ISOAbbreviation></Journal><ArticleTitle>International cohort of 382 children with lupus nephritis - presentation, treatment and outcome at 24&#xa0;months.</ArticleTitle><Pagination><StartPage>3699</StartPage><EndPage>3709</EndPage><MedlinePgn>3699-3709</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00467-023-06018-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Children with lupus have a higher chance of nephritis and worse kidney outcome than adult patients.</AbstractText><AbstractText Label="METHODS">We retrospectively analyzed clinical presentation, treatment and 24-month kidney outcome in a cohort of 382 patients (&#x2264;&#x2009;18&#xa0;years old) with lupus nephritis (LN) class&#x2009;&#x2265;&#x2009;III diagnosed and treated in the last 10&#xa0;years in 23 international centers.</AbstractText><AbstractText Label="RESULTS">The mean age at onset was 11&#xa0;years 9&#xa0;months and 72.8% were females. Fifty-seven percent and 34% achieved complete and partial remission at 24-month follow-up, respectively. Patients with LN class III achieved complete remission more often than those with classes IV or V (mixed and pure). Only 89 of 351 patients maintained stable complete kidney remission from the 6<sup>th</sup> to 24<sup>th</sup> months of follow-up. eGFR&#x2009;&#x2265;&#x2009;90&#xa0;ml/min/1.73&#xa0;m<sup>2</sup> at diagnosis and biopsy class III were predictive of stable kidney remission. The youngest and the oldest age quartiles (2y-9y,&#xa0;5m) (14y, 2m-18y,2m) showed lower rates of stable remission (17% and 20.7%, respectively) compared to the two other age groups (29.9% and 33.7%), while there was no difference in gender. No difference in achieving stable remission was found between children who received mycophenolate or cyclophosphamide as induction treatment.</AbstractText><AbstractText Label="CONCLUSION">Our data show that the rate of complete remission in patients with LN is still not high enough. Severe kidney involvement at diagnosis was the most important risk factor for not achieving stable remission while different induction treatments did not impact outcome. Randomized treatment trials involving children and adolescents with LN are needed to improve outcome for these children. A higher resolution version of the Graphical abstract is available as Supplementary information.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Mutiis</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2969-7094</Identifier><AffiliationInfo><Affiliation>Paediatric Unit, Maggiore Hospital, Azienda USL, Bologna, Italy. chiarademutiis@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenderfer</LastName><ForeName>Scott E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Pediatric Nephrology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Biswanath</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Pediatric Nephrology, Department of Pediatrics, Nilratan Sircar Medical College and Hospital, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagga</LastName><ForeName>Arvind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orjuela</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Nephrology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sar</LastName><ForeName>Tanmoy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pediatric Nephrology, Department of Pediatrics, Nilratan Sircar Medical College and Hospital, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Amita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Avinash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Sawai Mansingh Medical College, Jaipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>Hui-Kim</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teo</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Yokohama City University, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohnishi</LastName><ForeName>Ai</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Yokohama City University, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infection and Immunology, Aichi Children's Health and Medical Center, Obu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasapcopur</LastName><ForeName>Ozgur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Nephrology, Rheumatology and Dermatology, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrangelo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogura</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shima</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rianthavorn</LastName><ForeName>Pornpimol</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Clovis A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Children's Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trindade</LastName><ForeName>Vitor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Children's Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianviti</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Dialysis, Children's Hospital Bambino Ges&#xf9;, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akinori</LastName><ForeName>Miyazono</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Riku</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujimura</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minamikawa</LastName><ForeName>Shogo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamiyoshi</LastName><ForeName>Naohiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaito</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimori</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Aijinkai Takatsuki General Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannuzzella</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tullus</LastName><ForeName>Kjell</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Paediatric Nephrology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pediatr Nephrol</MedlineTA><NlmUniqueID>8708728</NlmUniqueID><ISSNLinking>0931-041X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Induction treatment</Keyword><Keyword MajorTopicYN="N">Kidney outcome</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37221349</ArticleId><ArticleId IdType="doi">10.1007/s00467-023-06018-5</ArticleId><ArticleId IdType="pii">10.1007/s00467-023-06018-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oni L, Wright RD, Marks S, Beresford MW, Tullus K (2021) Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 36:1377&#x2013;1385</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-020-04686-1</ArticleId><ArticleId IdType="pubmed">32725543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett M, Brunner HI (2013) Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am 39:833&#x2013;853</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2013.05.001</ArticleId><ArticleId IdType="pubmed">24182857</ArticleId><ArticleId IdType="pmc">4980821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM (2017) Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 76:2009&#x2013;2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B,&#xa0;Brogan P, Dolezalova P, Feldman B, Kone-Paut I, Lahdenne P, Marks SD, McCann L, Ozen S, Pilkington C, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76:1965&#x2013;1973</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211898</ArticleId><ArticleId IdType="pubmed">28877866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int (Suppl 2):221&#x2013;232</Citation></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, D&#xf6;rner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771&#x2013;1782</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201940</ArticleId><ArticleId IdType="pubmed">22851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhlrie A, Hennies I, Gellermann J, B&#xfc;scher A, Hoyer P, Waldegger S,&#xa0;Wygoda S, Beetz R, Lange-Sperandio B, Klaus G, Konrad M, Holder M, Staude H, Rascher W, Oh J, Pape L, T&#xf6;nshoff B, Haffner D; German Society of Paediatric Nephrology (2020) Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol 35:1235&#x2013;1246</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-020-04501-x</ArticleId><ArticleId IdType="pubmed">32193650</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz GS, D&#x2019;Agati VD (2007) The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 71:491&#x2013;495</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5002118</ArticleId><ArticleId IdType="pubmed">17264872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT,&#xa0;D'Agati VD, Ferrario F, Haas M, Jennette JC, Joh K, Nast CC, No&#xeb;l LH, Rijnink EC, Roberts ISD, Seshan SV, Sethi S, Fogo AB (2018) Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789&#x2013;796</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Laboratory Handbook Group (2021) Sheffield Children&#x2019;s Hospital NHSFT Laboratory Handbook 2021. NHS Foundation Trust</Citation></Reference><Reference><Citation>Schwartz GJ, Mu&#xf1;oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629&#x2013;637</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008030287</ArticleId><ArticleId IdType="pubmed">19158356</ArticleId><ArticleId IdType="pmc">2653687</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, Subcommittee on screening and management of high blood pressure in children (2017) Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 140:e20171904</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2017-1904</ArticleId><ArticleId IdType="pubmed">28827377</ArticleId></ArticleIdList></Reference><Reference><Citation>De Mutiis C, Wenderfer SE, Orjuela A, Bagga A, Basu B, Sar T,&#xa0;Aggarwal A, Jain A, Yap HK, Ito S, Ohnishi A, Iwata N, Kasapcopur O, Laurent A, Mastrangelo A, Ogura M, Shima Y, Rianthavorn P, Silva CA, Trindade V, Dormi A, Tullus K (2022) Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology (Oxford) 61:2563&#x2013;2571</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab746</ArticleId><ArticleId IdType="pubmed">34626102</ArticleId></ArticleIdList></Reference><Reference><Citation>World Bank (2021) Data: Country Classification, Low-Income Countries. World Bank Country and Lending Groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 . Accessed 12 Dec 2021</Citation></Reference><Reference><Citation>Rianthavorn P, Buddhasri A (2015) Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis. Pediatr Nephrol 30:1969&#x2013;1976</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-015-3138-y</ArticleId><ArticleId IdType="pubmed">26054714</ArticleId></ArticleIdList></Reference><Reference><Citation>Askenazi D, Myones B, Kamdar A, Warren R, Perez M, De Guzman M,&#xa0;Minta A, Hicks MJ, Kale A (2007) Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 22:981&#x2013;986</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-007-0447-9</ArticleId><ArticleId IdType="pubmed">17334789</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J,&#xa0;Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM (2019) Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 28:613&#x2013;620</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319836712</ArticleId><ArticleId IdType="pubmed">30871425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M, Muscal E, Eldin K, Hicks MJ, Sagcal-Gironella ACP, DeGuzman M, Wenderfer SE (2017) Clinical presentation and outcomes of childhood-onset membranous lupus nephritis. Pediatr Nephrol 32:2283&#x2013;2291</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-017-3743-z</ArticleId><ArticleId IdType="pubmed">28717937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson JE, Fu Q, Ji B, Rao S, Roth D, Magder LS,&#xa0;Petri M (2018) Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. J Rheumatol 45:671&#x2013;677</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161554</ArticleId><ArticleId IdType="pubmed">29496892</ArticleId><ArticleId IdType="pmc">5932209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, O&#x2019;Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C,&#xa0;Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarc&#xf3;n GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 55:252&#x2013;262</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev311</ArticleId><ArticleId IdType="pubmed">26342222</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL,&#xa0;Lau CS, Wong AK, Tong MK, Chan KW, Lai KN&#xa0;(2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156&#x2013;1162</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200010193431604</ArticleId><ArticleId IdType="pubmed">11036121</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D,&#xa0;Li LS, Mysler E, S&#xe1;nchez-Guerrero J, Solomons N, Wofsy D (2009) Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103&#x2013;1112</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId><ArticleId IdType="pubmed">19369404</ArticleId><ArticleId IdType="pmc">2678035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K,&#xa0;Bruijn JA, Bajema IM (2017) Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. Clin J Am Soc Nephrol 12:734&#x2013;743</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.10601016</ArticleId><ArticleId IdType="pubmed">28473317</ArticleId><ArticleId IdType="pmc">5477219</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D&#x2019;Cruz D, Sebastiani GD, de Ramon GE, Danieli MG,&#xa0;Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, G&#xfc;l A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934&#x2013;3940</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20666</ArticleId><ArticleId IdType="pubmed">15593207</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C,&#xa0;Iqbal K, Lenz O, Asif A, Nahar N, Leclerq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida Suarez M, Busse JC, Esquenazi M, Esquenazi A, Garcia Mayol L, Garcia Estrada H (2005) Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14:890&#x2013;895</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203305lu2238oa</ArticleId><ArticleId IdType="pubmed">16335581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA (2015) Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol 34:93&#x2013;97</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2802-0</ArticleId><ArticleId IdType="pubmed">25373448</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Broder A, Guan H, Yazdany J, Costenbader KH (2018) Sex Differences in Healthcare Utilization, End-stage Renal Disease and Mortality among Medicaid Beneficiaries with Incident Lupus Nephritis. Arthritis Rheumatol 70:417&#x2013;426</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40392</ArticleId><ArticleId IdType="pubmed">29193893</ArticleId><ArticleId IdType="pmc">5826885</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A,&#xa0;Li Vecchi M, Messa P, Sinico RA (2009) Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 68:234&#x2013;237</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.094508</ArticleId><ArticleId IdType="pubmed">18718989</ArticleId></ArticleIdList></Reference><Reference><Citation>Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 23:1891&#x2013;1896</Citation><ArticleIdList><ArticleId IdType="pubmed">8923362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannemuddhu SS, Shoemaker LR, Bozorgmehri S, Borgia RE, Gupta N, Clapp WL, Zeng X, Modica RF (2023) Does kidney biopsy in pediatric lupus patients &#x201c;complement&#x201d; the management and outcomes of silent lupus nephritis? Lessons learned from a pediatric cohort. Pediatr Nephrol. https://doi.org/10.1007/s00467-022-05859-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-022-05859-w</ArticleId><ArticleId IdType="pubmed">36688943</ArticleId><ArticleId IdType="pmc">10393877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>